These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 30746789

  • 1. Coadministration of epigallocatechin-3-gallate (EGCG) and caffeine in low dose ameliorates obesity and nonalcoholic fatty liver disease in obese rats.
    Yang Z, Zhu MZ, Zhang YB, Wen BB, An HM, Ou XC, Xiong YF, Lin HY, Liu ZH, Huang JA.
    Phytother Res; 2019 Apr; 33(4):1019-1026. PubMed ID: 30746789
    [Abstract] [Full Text] [Related]

  • 2. Decaffeinated green tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity mice.
    Santamarina AB, Carvalho-Silva M, Gomes LM, Okuda MH, Santana AA, Streck EL, Seelaender M, do Nascimento CM, Ribeiro EB, Lira FS, Oyama LM.
    J Nutr Biochem; 2015 Nov; 26(11):1348-56. PubMed ID: 26300331
    [Abstract] [Full Text] [Related]

  • 3. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice.
    Gan L, Meng ZJ, Xiong RB, Guo JQ, Lu XC, Zheng ZW, Deng YP, Luo BD, Zou F, Li H.
    Acta Pharmacol Sin; 2015 May; 36(5):597-605. PubMed ID: 25891086
    [Abstract] [Full Text] [Related]

  • 4. Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice.
    Lee MS, Kim CT, Kim Y.
    Ann Nutr Metab; 2009 May; 54(2):151-7. PubMed ID: 19390166
    [Abstract] [Full Text] [Related]

  • 5. Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet.
    Huang J, Li W, Liao W, Hao Q, Tang D, Wang D, Wang Y, Ge G.
    Food Funct; 2020 Nov 18; 11(11):9924-9935. PubMed ID: 33095225
    [Abstract] [Full Text] [Related]

  • 6. TEAVIGO (epigallocatechin gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass.
    Wolfram S, Raederstorff D, Wang Y, Teixeira SR, Elste V, Weber P.
    Ann Nutr Metab; 2005 Nov 18; 49(1):54-63. PubMed ID: 15735368
    [Abstract] [Full Text] [Related]

  • 7. Combined use of epigallocatechin-3-gallate (EGCG) and caffeine in low doses exhibits marked anti-obesity synergy through regulation of gut microbiota and bile acid metabolism.
    Zhu MZ, Zhou F, Ouyang J, Wang QY, Li YL, Wu JL, Huang JA, Liu ZH.
    Food Funct; 2021 May 11; 12(9):4105-4116. PubMed ID: 33977918
    [Abstract] [Full Text] [Related]

  • 8. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice.
    Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS.
    J Nutr; 2008 Sep 11; 138(9):1677-83. PubMed ID: 18716169
    [Abstract] [Full Text] [Related]

  • 9. Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization.
    Du Y, Paglicawan L, Soomro S, Abunofal O, Baig S, Vanarsa K, Hicks J, Mohan C.
    Nutrients; 2021 Feb 11; 13(2):. PubMed ID: 33670347
    [Abstract] [Full Text] [Related]

  • 10. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.
    Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, Fung ML, Tipoe GL.
    Eur J Nutr; 2014 Feb 11; 53(1):187-99. PubMed ID: 23515587
    [Abstract] [Full Text] [Related]

  • 11. Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men.
    Bérubé-Parent S, Pelletier C, Doré J, Tremblay A.
    Br J Nutr; 2005 Sep 11; 94(3):432-6. PubMed ID: 16176615
    [Abstract] [Full Text] [Related]

  • 12. Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease.
    Chen C, Liu Q, Liu L, Hu YY, Feng Q.
    Mol Nutr Food Res; 2018 Jan 11; 62(1):. PubMed ID: 28799714
    [Abstract] [Full Text] [Related]

  • 13. Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice.
    Kasture SB, Gaikar M, Kasture V, Arote S, Salve B, Rosas M, Cotti E, Acquas E.
    Behav Pharmacol; 2015 Feb 11; 26(1-2):125-32. PubMed ID: 25144514
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high-fat diet.
    Chen N, Bezzina R, Hinch E, Lewandowski PA, Cameron-Smith D, Mathai ML, Jois M, Sinclair AJ, Begg DP, Wark JD, Weisinger HS, Weisinger RS.
    Nutr Res; 2009 Nov 11; 29(11):784-93. PubMed ID: 19932867
    [Abstract] [Full Text] [Related]

  • 16. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
    Ding Y, Sun X, Chen Y, Deng Y, Qian K.
    Eur J Pharmacol; 2015 Aug 15; 761():405-12. PubMed ID: 25967348
    [Abstract] [Full Text] [Related]

  • 17. Epigallocatechin-3-gallate ameliorates both obesity and autoinflammatory arthritis aggravated by obesity by altering the balance among CD4+ T-cell subsets.
    Byun JK, Yoon BY, Jhun JY, Oh HJ, Kim EK, Min JK, Cho ML.
    Immunol Lett; 2014 Aug 15; 157(1-2):51-9. PubMed ID: 24239847
    [Abstract] [Full Text] [Related]

  • 18. Effects of green tea polyphenol (-)-epigallocatechin-3-gallate on newly developed high-fat/Western-style diet-induced obesity and metabolic syndrome in mice.
    Chen YK, Cheung C, Reuhl KR, Liu AB, Lee MJ, Lu YP, Yang CS.
    J Agric Food Chem; 2011 Nov 09; 59(21):11862-71. PubMed ID: 21932846
    [Abstract] [Full Text] [Related]

  • 19. Epigallocatechin gallate alleviates non-alcoholic fatty liver disease through the inhibition of the expression and activity of Dipeptide kinase 4.
    Yang M, Yan R, Sha R, Wang X, Zhou S, Li B, Zheng Q, Cao Y.
    Clin Nutr; 2024 Aug 09; 43(8):1769-1780. PubMed ID: 38936303
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.